Please assess the completion status of the following clinical trial:

Trial Title: Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with breast cancer~* Currently taking an aromatase inhibitor (AI)~* Age \> 50 years of age~* Postmenopausal, or two years since last menstrual cycle~* Urogenital/vulvovaginal symptoms such as vaginal dryness and pain with intercourse~* Changes in sexual health quality of life/sexual functioning since starting AI therapy~Exclusion Criteria:~* The use of other treatments for breast cancer such as chemotherapy or radiation within the past 12 months~* A known sensitivity to medications containing testosterone~* The use of exogenous hormone replacement therapy (HRT) in the past three months, including systemic and local estrogen or testosterone therapy

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaginal Testosterone (Type: EXPERIMENTAL): Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).